DRW Securities’s Theravance Biopharma TBPH Stock Holding History

DRW Securities’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,304	Closed	-$459K	–	1459
2026 Q1	$459K	Buy	+28,304	New	+$501K	0.01%	650

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DRW Securities's TBPH Position: Q2 2026 in Review

DRW Securities sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 28,304 shares — an estimated $459K sold.

DRW Securities first reported a position in TBPH in Q1 2026 and held it in 1 quarter. The position peaked at $459K in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

DRW Securities reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 28,304 Theravance Biopharma shares in Q2 2026, an estimated $459K.
DRW Securities first reported a position in Theravance Biopharma in Q1 2026 and held it in 1 quarter.
DRW Securities's Theravance Biopharma position peaked at $459K in Q1 2026.
181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.